Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson's Disease, at Upcoming Scientific Meetings
Morgan Stanley Maintains Prime Medicine(PRME.US) With Hold Rating, Cuts Target Price to $5
Bristol-Myers Squibb (BMY.US) collaborates with Prime Medicine (PRME.US) to develop innovative cell therapy.
Prime Medicine will receive an upfront payment of $55 million and $55 million in private equity, and is eligible to receive over $3.5 billion in milestone payments.
H.C. Wainwright Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $10
Prime Medicine Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Prime Medicine's Strategic Alliances and Growth Potential Affirm Buy Rating